These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7734321)

  • 21. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
    Fang C; Shi B; Pei YY; Hong MH; Wu J; Chen HZ
    Eur J Pharm Sci; 2006 Jan; 27(1):27-36. PubMed ID: 16150582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo.
    Deng NH; Wang L; He QC; Zheng JC; Meng Y; Meng YF; Zhang CJ; Shen FB
    Drug Deliv; 2016; 23(1):95-100. PubMed ID: 24786488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice.
    Kaneda Y; Yamamoto Y; Kamada H; Tsunoda S; Tsutsumi Y; Hirano T; Mayumi T
    Cancer Res; 1998 Jan; 58(2):290-5. PubMed ID: 9443407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A genetically modified recombinant tumor necrosis factor-alpha conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chains.
    Savva M; Duda E; Huang L
    Int J Pharm; 1999 Jul; 184(1):45-51. PubMed ID: 10425350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation.
    Thamm DH; Kurzman ID; Clark MA; Ehrhart EJ; Kraft SL; Gustafson DL; Vail DM
    Clin Cancer Res; 2010 Mar; 16(5):1498-508. PubMed ID: 20160058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.
    Sun X; Yang Z; Li S; Tan Y; Zhang N; Wang X; Yagi S; Yoshioka T; Takimoto A; Mitsushima K; Suginaka A; Frenkel EP; Hoffman RM
    Cancer Res; 2003 Dec; 63(23):8377-83. PubMed ID: 14678999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.
    Inoue M; Ando D; Kamada H; Taki S; Niiyama M; Mukai Y; Tadokoro T; Maenaka K; Nakayama T; Kado Y; Inoue T; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2017 Apr; 292(16):6438-6451. PubMed ID: 28235800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.
    Yamamoto Y; Tsutsumi Y; Yoshioka Y; Nishibata T; Kobayashi K; Okamoto T; Mukai Y; Shimizu T; Nakagawa S; Nagata S; Mayumi T
    Nat Biotechnol; 2003 May; 21(5):546-52. PubMed ID: 12665803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Creation of functional muteins using phage libraries for pharmacoproteomic-based drug discovery and development of DDS].
    Yoshioka Y
    Yakugaku Zasshi; 2004 Aug; 124(8):531-9. PubMed ID: 15297722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
    Takakura T; Takimoto A; Notsu Y; Yoshida H; Ito T; Nagatome H; Ohno M; Kobayashi Y; Yoshioka T; Inagaki K; Yagi S; Hoffman RM; Esaki N
    Cancer Res; 2006 Mar; 66(5):2807-14. PubMed ID: 16510603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simple PEG modification of DNA aptamer based on copper ion coordination for tumor targeting.
    Takafuji Y; Jo J; Tabata Y
    J Biomater Sci Polym Ed; 2011; 22(9):1179-95. PubMed ID: 20615331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxystress inducing antitumor therapeutics via tumor-targeted delivery of PEG-conjugated D-amino acid oxidase.
    Fang J; Deng D; Nakamura H; Akuta T; Qin H; Iyer AK; Greish K; Maeda H
    Int J Cancer; 2008 Mar; 122(5):1135-44. PubMed ID: 17990314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice.
    Shalgunov V; Zaytseva-Zotova D; Zintchenko A; Levada T; Shilov Y; Andreyev D; Dzhumashev D; Metelkin E; Urusova A; Demin O; McDonnell K; Troiano G; Zale S; Safarovа E
    J Control Release; 2017 Sep; 261():31-42. PubMed ID: 28611009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate.
    Yang Z; Sun X; Li S; Tan Y; Wang X; Zhang N; Yagi S; Takakura T; Kobayashi Y; Takimoto A; Yoshioka T; Suginaka A; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Aug; 64(16):5775-8. PubMed ID: 15313919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG).
    Liu Z; Ren Y; Pan L; Xu HM
    Int J Mol Sci; 2011; 12(4):2650-63. PubMed ID: 21731464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer.
    Zhang X; Gan Y; Gan L; Nie S; Pan W
    J Pharm Pharmacol; 2008 Aug; 60(8):1077-87. PubMed ID: 18644200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin.
    Thomas JB; Holtsberg FW; Ensor CM; Bomalaski JS; Clark MA
    Biochem J; 2002 May; 363(Pt 3):581-7. PubMed ID: 11964159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of PVP as a polymeric carrier to improve the plasma half-life of drugs.
    Kaneda Y; Tsutsumi Y; Yoshioka Y; Kamada H; Yamamoto Y; Kodaira H; Tsunoda S; Okamoto T; Mukai Y; Shibata H; Nakagawa S; Mayumi T
    Biomaterials; 2004 Jul; 25(16):3259-66. PubMed ID: 14980420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.
    Libutti SK; Paciotti GF; Byrnes AA; Alexander HR; Gannon WE; Walker M; Seidel GD; Yuldasheva N; Tamarkin L
    Clin Cancer Res; 2010 Dec; 16(24):6139-49. PubMed ID: 20876255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.